Wednesday, July 15, 2026

Search
HomeHealth NewsHigh-dose risankizumab trial tests staying power against psoriasis
Health News

High-dose risankizumab trial tests staying power against psoriasis

0
4
- Advertisement -

Short-term (Weeks 0–28) secondary efficacy endpoints associated with high induction doses of risankizumab at Weeks 0, 4, and 16. Credit: Nature Communications (2025). DOI: 10.1038/s41467-025-67475-0

Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that paired…

Click here to view the original article.

- Advertisment -
Previous article
Costs pose hurdle for promising new hepatitis C lab test
Next article
Queen Mary of Denmark dazzles in a favourite diamond tiara as she leads the glamour at the New Year’s Day gala in Copenhagen

RELATED ARTICLES

- Advertisement -

Recently Viewed

Load more

FEATURED

POPULAR POSTS

POPULAR CATEGORY

The Australian Online News Network acknowledges the traditional custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.

FOLLOW US

© 2024 Australian Online News | Privacy Policy